Connor Clark & Lunn Investment Management Ltd. Buys 259,463 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 750.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 294,037 shares of the company’s stock after purchasing an additional 259,463 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.64% of Omnicell worth $12,820,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its stake in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the period. GAMMA Investing LLC raised its position in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the period. EntryPoint Capital LLC lifted its stake in shares of Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares during the last quarter. CWM LLC boosted its holdings in shares of Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. grew its stake in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Trading Up 5.5 %

NASDAQ OMCL opened at $44.11 on Friday. The business has a fifty day simple moving average of $44.19 and a 200 day simple moving average of $37.20. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74. The firm has a market capitalization of $2.04 billion, a P/E ratio of -109.69, a PEG ratio of 35.67 and a beta of 0.81.

Wall Street Analysts Forecast Growth

OMCL has been the topic of a number of research reports. Wells Fargo & Company upped their price objective on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday. Craig Hallum boosted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.